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Aims and objectives 
The aim of this discussion paper is to enable nurses to understand how 
deoxyribonucleic acid analysis can be predictive for some diseases and not 
predictive for others. This will facilitate nurses to interpret genomic test results and 
explain them to patients.     
Background 
Advances in technology mean that genetic testing is now commonly performed by 
sequencing the majority of an individual’s genome or exome.  This results in a huge 
amount of data, some of which can be used to predict or diagnose disease.    
Design 
This is a discussion paper. 
Methods 
This paper emerged from multiple discussions between the three authors over many 
months, culminating in a writing workshop to prepare this text.  
Results 
The results of DNA analysis can be used to diagnose or predict rare diseases that 
are caused by a mutation in a single gene. However, while there are a number of 
genetic factors that contribute to common diseases, the ability to predict whether an 
individual will develop that condition is limited by the overall heritability of the 
condition.   Environmental factors (such as lifestyle) are likely to be more useful in 
predicting common disease than genomic testing.  Genomic tests may be of use to 
inform management of diseases in specific situations.     
Conclusions 
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Genomic testing will be of use in diagnosing disorders due to single gene mutations, 
but the use of genomic testing to predict the chance of a patient being affected in the 
future by a common disease is unlikely to be a realistic option within a health service 
setting.   
Relevance to clinical practice 
Nurses will increasingly be involved in the use of genomic tests in mainstream 
patient care.  However, they need to understand and be able to explain to patients 
the practical applications of and limitations of such tests.      
 
Summary box 
What does this paper contribute to the wider global clinical community? 
• Genomic testing enables a person’s genome to be studied 
• Genomic testing is useful in diagnosis or prediction of rare genetic disorders 
• Due to the low heritability of many conditions, it is unlikely that results of 
genomic tests will be of practical utility in predicting common disease.   
Key words  
Nursing, genomic, genetic, predictive power, heritability, gene association, genetic 
susceptibility, pharmacogenomics.  
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Genetics and genomics (see Box 1) are increasingly part of mainstream healthcare.  
The aim of this discussion paper is to enable nurses to understand how DNA 
analysis (used in both genetic and genomic contexts) can be predictive for some 
diseases and not predictive for others. This will facilitate nurses to interpret DNA 
results and explain them to patients.   
 
Background 
Historically, genetic testing has been offered to patients affected by or at risk of a 
rare genetic condition that is known to be caused by a variation in a single gene.     
Targeted tests have enabled analysis of a specific sequence of deoxyribonucleic 
acid (DNA) in a gene or genes associated with the condition. Due to advances in 
technology, it is now becoming more efficient to perform a test which results in a 
sequence of the majority of the individuals’ DNA or the coding sequences (exons) 
within the DNA (Korf 2013).   
 
Genome sequencing (for definition, see Box 2) is envisioned to ultimately replace 
conventional forms of genetic testing (Manolio et al. 2013, Wright et al. 2013). The 
technology will become so inexpensive that it will be straightforward to sequence the 
entire genome and only interpret the loci of interest. This prospect has already led to 
an intense debate on what to do with the remaining unreported data (Burke et al. 
2013, Green et al.2013). The return of unexpected, or ‘incidental’, findings is one of 
many concerns accompanying the introduction of genome sequencing in health care. 
Others include issues around privacy, discrimination, insurability, and patient and 
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consumer protection (Hens et al. 2013, Jackson et al. 2012), all of which have 
relevance to holistic nursing care.   
 
The announcement of the projects such as the 100,000 genome project in England 
(Genomics England 2014), a transformative programme for the National Health 
Service is an additional impetus for the whole health service workforce to engage 
with genomics.  As whole genome and whole exome sequencing (Box 2) is 
introduced into health care the landscape of genetic testing will drastically change 
(Manolio et al. 2013) because the information that is obtained from sequencing is 
much more complex than the results of traditional genetic testing.  Where 
traditionally a test was undertaken to inform a single health outcome, genome 
sequencing can inform the diagnosis of, or susceptibility to, numerous diseases 
(Ashley et al.2010).  Increasingly nurses are involved in offering genetic testing and 
may therefore be asked to explain tests based on sequencing, to obtain informed 
consent and to explain results.  It is therefore important that they understand the 
power of such tests to predict specific conditions in the patient.  
 .   
It is claimed that there are opportunities for the results of genomic tests to detect and 
inform management of disease (Downing et al, 2011), however this depends in large 
part on the predictive ability of a test. The predictive ability determines whether the 
test is able to distinguish a group of people who have a higher risk of disease than 
others. How much higher their risk needs to be, depends on the potential harms and 
benefits of correct and incorrect medical decisions that follow the test results. 
Therefore, the discussion of these concerns in the context of sequencing should start 
from a critical assessment of the predictive ability of DNA, which is paramount 
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because the genome does not have an ‘overall’ predictive ability as such. Rather, 
genome sequencing should be seen as one assay that consists of numerous tests 
(Zimmern & Kroese 2007 ). The predictive ability depends on what is predicted, in 
whom and how (using which specific information from the DNA).  
 
For a constructive debate on clinical and ethical issues, health care professionals 
need to be aware of the possibilities and limitations of sequencing. A good 
understanding of what can (and cannot) be predicted from our DNA is necessary to 
ensure a responsible introduction of genome sequencing in health care and an 
effective regulation of commercial DNA testing.  
 
Design 
This is a discussion paper. The focus of the paper was developed as a result of the 
authors’ involvement in an expert group on genetic testing, where it became 
apparent through discussions that there was a lack of understanding in health 
professionals of the predictive power of genetic tests.   
 
Method 
The authors formed a small nominal group to develop the paper. All of the authors 
have long-standing expertise in genomic healthcare and two are nurses.  Initially, 
discussions on the content focussed on the breadth of genetic tests and the use of 
those tests.  A draft paper was written: a face to face meeting was then convened to 
enable the authors to discuss in depth the relevance of the material to nurses in 
practice.  The final paper was the result of consensus between all three authors.   
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What determines predictive ability?  
The predictive ability of a test is determined by the incidence of disease, the 
frequency of the mutation (or polymorphism) and the association between the 
mutation and the disease. These three parameters uniquely specify the contingency 
table from which all test performance measures can be calculated (Box 3). For 
prediction, the association is of key importance: the stronger the association, the 
higher the risk difference between carriers and non-carriers of the mutation. Yet, 
strong association alone is not enough. 
 The incidence drives the absolute risk for carriers and non-carriers: the 
positive and negative predictive value. If the disease is common, the risks in those 
who carry the gene variation can be markedly increased even when the association 
is not strong, but if the disease is rare, even very strong association will yield 
relatively low absolute risks in carriers. A 2-fold increase of an average (prior) risk of 
30%, increases the risk to maximally 60%, but a 10-fold increase of a prior risk of 
0.1%, increases the risk for carriers maximally to 1%—much higher than the prior 
risk, but still low.   
 Finally, the frequency of the mutation drives the sensitivity and specificity of 
the test. When a disease is common but the mutation is rare, the sensitivity remains 
low even when the association is very strong, simply because most patients will not 
carry the mutation. Carrying a strongly-associated rare mutation will substantially 
increase the risk of disease, but only in a small minority of patients.  
 
What can a DNA sequence reveal?  
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The predictive ability of DNA depends on the degree to which genes contribute to the 
development of disease (or other health outcome of interest), the heritability 
(Janssens et al.2006). We discuss the three most common types of outcomes that 
are predicted from DNA and which vary in genetic origin and degree of heritability: 
monogenic disorders, treatment outcomes and susceptibility to common diseases.  
 
Monogenic disorders 
Inherited single gene disorders are conditions caused by changes to specific single 
genes, with no or very little impact from environmental factors. There is robust 
evidence for many genes associated with specific conditions, investigated in families, 
and there is emerging scientific consensus over methods of assigning causative 
genes to diseases and determining the pathogenicity of mutations in monogenic 
disorders (Kenna et al.2013).  
 The predictive ability of genetic testing for monogenic disorders, or monogenic 
subsets of multifactorial diseases, is very high when the mutations are known. 
Genetic testing can be used to diagnose the disease, in symptomatic and 
asymptomatic phases of the disease; to test family members of patients who wish to 
know about their future disease; to test prenatally and enable choices about the 
management of the pregnancy; and, before pregnancy, to identify couples at high 
risk of having a child affected by an autosomal recessive condition.  
Mutation testing for monogenic diseases is very predictive, but its usefulness 
depends on the purpose of testing and on the populations and mutations that are 
tested. For example, DNA testing for autosomal dominant mutations that cause 
mature onset diabetes of the young (MODY) (Shepherd et al.2001) might be useful 
for relatives of MODY patients, but is unlikely to benefit the prevention of diabetes in 
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the general population; the sensitivity of MODY testing is too low because most 
people will develop diabetes through other causes. The interpretation of genetic tests 
results also warrant caution when not all mutations are known or tested. In these 
situations, the presence of mutations is very informative (high positive predictive 
value), but the absence is not (low negative predictive value) because individuals 
who do not have the tested mutations may still carry others.  
 
Treatment outcomes  
Pharmacogenomics targets variations in the genome that are related to treatment 
response, dosing and adverse side effects. Several genes, such as those in the 
cytochrome (CYP) and human leukocyte antigen (HLA) gene groups (Sim et al. 
2013, Wei et al. 2012), are associated with responses to a wide range of 
medications. Some associations are extremely strong and make genetic testing an 
evident first step in decisions about treatment, whereas others are much weaker yet 
statistically significant. An example of the first is HLA-B*5701 and hypersensitivity 
reactions to abacavir, a treatment that reduces the amount of virus in the blood of 
HIV patients (Thompson et al.2012). An example of the second is CYP2C19 and 
clopidogrel, which reduces the risk of adverse cardiovascular events after coronary 
stenting (Holmes et al.2011), but maybe not enough to justify pharmacogenetic 
testing. The scientific basis of most pharmacogenomic associations is far less robust 
than tests for monogenic disorders, although in some specific examples (as above) 
the clinical use of these associations will be valuable.  
 
Susceptibility to common diseases 
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Most common diseases, such as cardiovascular disease, type 2 diabetes and 
asthma, are caused by a complex interplay of many genetic and environmental risk 
factors. Single risk factors, whether genetic or non-genetic, typically have only a 
minor impact on disease risk.  
 Genetic prediction of common disease is done using risk models in which the 
effects of multiple genetic variants are considered simultaneously. The assessment 
of the predictive ability follows the same principles as presented in Box 3, albeit more 
complex. There is not one odds ratio and frequency to consider, but many, and there 
is not one combination of sensitivity and specificity, but a range that is known as the 
receiver operating characteristic (ROC) curve (Hanley & McNeil 1982). Similarly, 
there is not one positive predictive value and negative predictive value, but again a 
range, the risk distribution. 
 For most diseases the predictive ability of genetic testing is limited and far 
lower than risk models that are based on non-genetic risk factors such as diet, 
exercise, alcohol consumption and smoking (Bao et al. 2013). However, there are 
exceptions. For example, the predictive ability of genetic testing for age-related 
macular degeneration and coeliac disease is substantially higher because the risk 
models include one or more variants that are strongly associated with disease risk 
(Romanos et al. 2013, Seddon et al. 2013). 
 While the predictive ability is expected to increase with more discoveries of 
susceptibility variants, it may not become high. Since the maximum predictive ability 
is limited by the heritability (Table 1), genome sequencing will predict diseases with 
varying degrees of accuracy even if the genetic origins of diseases are completely 
understood. This moderate predictive ability implies that the genetic prediction of 
common diseases will likely have limited utility for health care. It was argued that 
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DNA testing could be used to motivate people to adopt a healthier lifestyle, but 
multiple studies have not shown such motivational effects (Bize et al. 2012). Whether 
the predictive ability is high enough to stratify screening programs, such as 
mammography screening for breast cancer, remains to be investigated (Chowdhury 
et al. 2013). 
 
Conclusions 
Achieving understanding of the concept and determinants of predictive ability will put 
into perspective some of the main concerns expressed in relation to DNA 
sequencing. First, the use of genomic testing to predict the chance of a patient being 
affected in the future by a common disease is unlikely to be a realistic option within a 
health service setting.  This is because many different genetic variants, as well as 
environmental influences, contribute to development of common diseases.  Second, 
for the same reason as above, although there may be unexpected findings as a 
result of genomic testing, these are unlikely to be of relevance to patient care unless 
they relate to mutations in genes known to cause single gene disorders. Third, 
genetic discrimination and stigmatisation on the basis of multifactorial traits is not 
realistic, as the predictive value of DNA testing is too low. It is unlikely that insurance 
companies can use genetic information to differentiate those at high or low risk of 
common diseases with any degree of practicality.  
In terms of nursing education and practice, it is clear that nurses have a role in 
informing and guiding patients who are considering genetic testing.  It can be argued 
that it is not ethical to raise expectations of the utility of genetic test results 
inappropriately but, in order to help patients set reasonable expectations, nurses 
must be informed themselves about these issues.  In addition, nurses have a duty to 
Formatted: Font color: Red
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help ensure that scarce health resources are used wisely and, whether testing is 
funded by the state, insurance company or the patient, expenditure that will not 
substantively contribute to patient health and wellbeing should be avoided.    
 
While it is important that genetics and genomics are taught within in nursing 
curricula, equally important are the applications of these sciences to healthcare.  As 
these topics are relevant to virtually every aspect of health and disease, we would 
suggest that encouraging discussion of how genetics and genomics apply in health 
promotion, disease prevention and disease management across the range of 
systems will encourage nurses to think about the issues more readily when in 
practice.  A wide range of possible examples can also be used as the focus for 
discussion of ethical and professional practice, as well as stimulating nurses to think 
about the evidence base for care, for example the use of pharmacogenomic testing.     
 Ethical and societal discussions of the introduction of genome sequencing 
should be based on what can and cannot be predicted. Use of DNA testing can be 
very informative for diagnosing monogenic disorders and syndromes and for non-
genetic purposes as ancestry, paternity and forensic testing, but it is not so 
predictive for most common diseases and traits. A patient’s DNA may tell us more 
about the past and present than about the future. 
 
Relevance to clinical practice 
When explaining genomic tests and/or results to patients, it is important to 
differentiate between test results that can offer predictive information for the patient, 
and those with less relevance to their healthcare.   Patients should be aware that 
unexpected findings could result from the use of genomic approaches to testing their 
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DNA.  Use of genomic testing to identify gene variants that could predispose the 
patient to common diseases are unlikely to of consequence in the context of 
insurance.   However, genomic testing may help to inform choice of therapy in the 
management of some specific conditions.  
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Box 1. Definitions of genetics and genomics according to the World Health 
Organisation (2015) 
Genetics is the study of heredity  
Genomics is defined as the study of genes and their functions, and related techniques.  
The main difference between genomics and genetics is that genetics scrutinises the 
functioning and composition of the single gene whereas genomics addresses all genes and 
their inter relationships in order to identify their combined influence on the growth and 
development of the organism.          (World Health Organisation,2015) 
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Box 2. Definitions of genome and sequence 
Genome 
Complete genetic  information encoded by a persons DNA 
Genome sequence 
The order of the bases or DNA nucleotides in the genome.  Other relevant terms are: 
Targeted sequence -sequencing a specific portion of the DNA eg specific genes such as 
BRCA1 and BRCA2 
Exome sequence- sequencing the exons of genes-the portions of the gene that codes for 
proteins 
Whole genome sequence- sequencing the total genome. 
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Box 1 Calculation of predictive ability 
 
 
  Disease  
  Yes No Total 
Mutation Present  a b a+b 
 Absent c d c+d 
 Total a+c b+d n 
 
This table can be uniquely constructed from three parameters: 
- Disease risk, e.g., the 10-year incidence: (a+c)/n 
- Frequency of mutation: (a+b)/n 
- Strength of association between mutation and disease risk: 
 Odds Ratio (OR): ad/bc, or 
 Relative Risk (RR): (a/(a+b))/(c/(c+d) 
 
From the table, all test performance characteristics can be calculated: 
- Sensitivity (Se): a/(a+c) 
- Specificity (Sp): d/(b+d) 
- Positive Predictive Value (PPV): a/(a+b) 
- Negative Predictive Value (NPV): d/(c+d) 
- Likelihood Ratio of positive result (LR+): (a/b) / ((a+c)/(b+d)) = Se / (1-Sp) 
- Likelihood Ratio of negative result (LR-): (c/d) / ((a+c)/(b+d)) = (1-Se) / Sp  
- Risk Difference: (a/(a+b)) - (c/(c+d)) 
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Table 1. Heritability estimates of various complex diseases and traits 
 
Disease or trait Heritability 
Eye color >99% 
Type 1 diabetes 88% 
Schizophrenia 81% 
Alzheimer’s disease 79% 
Height 70-87% (m), 68-85% (w) 
Obesity 65-84% (m), 64-79% (w) 
Smoking persistence 59% (m), 46% (w) 
Anorexia nervosa 56% 
Rheumatoid arthritis 53-65% 
Panic disorder 43% 
Prostate cancer  42% 
Migraine 40-50% 
Heart attack 38% (m), 57% (w) 
Smoking initiation 37% (m), 55% (w) 
Depression 37% 
Colorectal cancer 35% 
Anxiety disorder 32% 
Homosexuality 30% (m), 50-60% (w) 
Breast cancer 27% 
Type 2 diabetes 26% 
Lung cancer 26% 
Happiness 22% (m), 41% (w) 
 
Table 1 is adapted from (Janssens & van Duijn). Heritability and frequency estimates 
are obtained from published studies and meta-analyses. References for the 
heritability estimates are provided in the original table. m=men, w=women. 
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